Office Based Addiction Treatment Training and Technical Assistance (OBAT TTA)

A Resource for Healthcare and Social Services Professionals

Protecting the Community and Serving Your Patient: The Importance of Buprenorphine

Estimated time to complete: 0 hours 30 minutes

Part 3 describes the three medications that are mainly used for treating Opioid-Use Disorder, and dives deeper into buprenorphine prescribing and the pharmacy's role in it.


Register now

Description

"Protecting the Community and Serving Your Patient: The Importance of Buprenorphine" is Part 3 of 3 in the "Best Practices for Community Pharmacy-Based Care for Patients with Opioid Use Disorder" series. Part 3 describes the three medications that are mainly used for treating Opioid-Use Disorder, and dives deeper into buprenorphine prescribing and the pharmacy's role in it. 

Participants will be required to complete a pre-test, 30 minute recorded video, post-test and evaluation for the training. 0.5 contact hours will be awarded to pharmacists and pharmacy technicians who complete those requirements. However, it may take up to 30 days for the credit to be seen in the CPE Monitor profile for participants.

Intended audience

This activity is intended for pharmacists and pharmacy technicians working as part of the healthcare team to treat patients for substance use disorder.

Speakers

Jeffrey Bratberg

PharmD, FAPhA

University of Rhode Island Clinical Professor of Pharmacy Practice

Dr. Jeffrey Bratberg is well acquainted with the challenges community pharmacists and pharmacies face regarding opioid dispensing, safety, overdose and addiction. In 2012, Bratberg, along with a University of Rhode Island student pharmacist, co-developed an overdose education and naloxone training program for pharmacists in the first-in-nation statewide Collaborative Pharmacy Practice Agreement for naloxone. He is an unpaid consultant for prescribetoprevent.org, a website devoted to opioid overdose education and naloxone training, which hosts an online continuing professional education program that has trained over 10,000 pharmacists nationwide. In 2015, he was selected to serve as a member of the Rhode Island Governor’s Overdose Prevention and Intervention Task Force. He is a consultant or co-investigator on federal grants from the National Institute on Drug Abuse, Centers for Disease Control and Prevention, and Agency for Healthcare Research and Quality. Bratberg is the 2016 NASPA National Cardinal Health Generation Rx Award winner. The Generation Rx Champions Award honors a pharmacist who has demonstrated outstanding commitment to raising awareness of the dangers of Rx drug misuse among the general public, as well as the pharmacy community. Finally, Bratberg is the guest editor of the first ever special issue on Opioid Safety and Naloxone of the Journal of the American Pharmacists Association (Mar/April 2017).

Alyssa M. Peckham

PharmD, BCPP

Neuroscience Medical Science Liaison at Otsuka Pharmaceutical Companies

Dr. Alyssa Peckham is a board certified psychiatric clinical pharmacist specializing in various psychiatric and substance use disorders. She received her PharmD from the University of Rhode Island and completed two years of postgraduate residency training in psychiatry at the Veterans Affairs Hospital in Connecticut. Prior to her current role, she practiced as an advanced practice pharmacist in the Bridge Clinic at Massachusetts General Hospital in Boston which is a low threshold, harm reduction clinic for people with substance use disorders. Her research is focused on the use and misuse of prescriptions and other substances, with a focus on pharmacotherapy and harm reduction

Objectives

1. Describe the efficacy and safety of dispensing buprenorphine for opioid use disorder (OUD) treatment

2. Explain an effective interaction between a pharmacy staff member and patient filling a prescription for buprenorphine

Sponsored by

Boston Medical Center Office-Based Addiction Treatment Training and Technical Assistance +, The Association for Multidisciplinary Education and Research in Substance Use and Addiction, The Opioid Response Network (ORN)

Funding for this initiative was made possible (in part) by grant no. 1H79TI083343 from SAMHSA. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services; nor does mention of trade names, commercial practices, or organizations imply endorsement by the U.S. Government.

Accreditation information

Topic Designator: Disease State Management/Drug Therapy

Activity Type: Knowledge-based

Expires 12/9/2023

Pharmacist | UAN 0026-9999-21-082-H01-P

Pharmacy Technician | UAN0026-9999-21-082-H01-T

Accreditation

Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. Massachusetts College of Pharmacy and Health Sciences designates this educational activity for a total of 0.5 contact hours (0.05 CEUs).

Requirements for Credit

Credit will not be issued to participants who do not complete the pre-test, post-test and evaluation. Credit may take up to 30 days to reflect on the CPE Monitor profile for the participants.

Statement of Disclosure

Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education.  It is the policy of MCPHS University that the speakers and planning committee members disclose all financial relationships with ineligible companies, and that relevant conflicts of interest are mitigated.  Speakers will disclose any unlabeled/unapproved use of drugs or devices during their presentation.

Alyssa M. Peckham is employed by Otsuka Pharmaceutical Companies as a Neuroscience Medical Science Liaison.

Jeffery Bratberg holds no relevant financial relationship with ineligible companies.

All MCPHS CE staff members have no relevant financial relationships with ineligible companies to disclose.

Register now

OBAT TTA is a program of Boston Medical Center (BMC), a 514-bed academic medical center located in Boston's historic South End and the largest safety-net hospital in New England.

Funding for OBAT TTA is provided by:

Commonwealth of Massachusetts Department of Public Health
Massachusetts Department of Public Health Bureau of Substance Abuse Services (BSAS)
GE Foundation

© 2021 Boston Medical Center. All rights reserved. Site by Signal.